Research programme: small molecule therapeutics - FoxBio
Latest Information Update: 28 Aug 2022
Price :
$50 *
At a glance
- Originator Antoxerene
- Developer FoxBio
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for research development in Unspecified in USA
- 12 Jul 2018 Antoxerene launches a joint venture with Juvenescence Limited called FoxBio for development of senolytic small molecules
- 12 Jul 2018 Early research in Undefined indication in USA (unspecified route)